ADVFN - Advanced Financial Network.
HOME» NASDAQ » M » MYL Stock Price » MYL Stock News

Mylan Inc. Share News

 Mylan Inc. (mm) Stock Price
MYL Stock Price
 Mylan Inc. (mm) Stock Chart
MYL Stock Chart
 Mylan Inc. (mm) Stock News
MYL Stock News
 Mylan Inc. (mm) Company Information
MYL Company Information
 Mylan Inc. (mm) Stock Trades
MYL Stock Trades

Mylan Confirms Endo Suit Over Generic Migraine Drug Application

DOW JONES NEWSWIRES Mylan Inc. (MYL) confirmed Wednesday that it has been sued by Endo Pharmaceuticals Holdings Inc. (ENDP) over its application for approval of a generic drug used to treat acute migraine headaches in adults. Mylan--one of the world's largest generic drug makers--said it believes it is the first company to file a substantially complete application for approval of frovatriptan succinate EQ, a generic version of Frova. The company said it expects to qualify for 180 days of marketing exclusivity upon final approval from the Food and Drug Administration. Mylan, which has had litigation-related charges figure prominently in its recent quarterly results, last month reported second-quarter earnings surged 70% as sales got a lift from a weaker dollar. Shares closed Tuesday at $20.01 and were inactive in recent premarket trade. Through the latest close, the stock is down 5.3% since the start of the year. -By Mia Lamar, Dow Jones Newswires; 212-416-3207;

Stock News for Mylan Inc. (MYL)
10/05/201509:11:00Mylan Schedules Third Quarter 2015 Financial Results Conference...
09/29/201508:09:00Drugs - Generic Equities at a Glance -- Mylan, Zoetis, Ironwood...
09/28/201507:30:00Mylan Launches Generic Invega® Tablets
09/24/201515:20:00Mylan Comments on Meritless Perrigo Lawsuit Filed Today in Israel
09/22/201508:42:00Equities Coverage on the Healthcare Sector - Novavax, Celgene...
09/21/201516:54:35Current Report Filing (8-k)
09/21/201509:00:00Mylan Moves to Cancel `Stichting` Takeover Defense
09/21/201507:30:00Mylan Foundation Requests Cancellation of Preferred Shares
09/18/201507:30:00Mylan Launches One of First Generic Lescol XL® Tablets
09/17/201507:50:00Perrigo Asks Shareholders to Reject Mylan's Latest Bid
09/15/201517:17:12Current Report Filing (8-k)
09/14/201510:42:00Mylan to Present at Morgan Stanley Global Healthcare Conference
09/14/201509:50:00Mylan Launches Offer for Perrigo
09/14/201509:41:00Perrigo Announcement Regarding Unsolicited Offer From Mylan N.V.
09/14/201509:12:56Automatic Shelf Registration Statement of Securities of Well-known...
09/14/201509:09:45Securities Registration: Employee Benefit Plan (s-8)
09/14/201508:30:00Mylan Commences Offer to Acquire Perrigo
09/14/201508:05:00Theravance Biopharma and Mylan Initiate Phase 3 Program for Revefenacin...
09/14/201507:30:00Mylan Launches Generic Unasyn® for Injection
09/11/201516:56:17Post-effective Amendment to an S-8 Filing (s-8 Pos)

Mylan Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations